Never-smoker patients with lung cancer respond poorly to ICB6 and the low responsiveness is thought to be associated with low tumor mutational burden (TMB), low neoantigen load and lower expression of programmed cell death-ligand 1 (PD-L1)7,8. Here, CD274 is linked to neoplasm.